Biodesix to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025
Biodesix (NASDAQ: BDSX) has scheduled its Q4 and full-year 2024 financial results announcement for March 3, 2025, after market close. The company will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the results and provide a business update. Management will conduct a question-and-answer session for analysts, and a replay will be available on the company's investor website approximately two hours after the call concludes. Participants are recommended to join 15 minutes before the start time.
Biodesix (NASDAQ: BDSX) ha programmato l'annuncio dei risultati finanziari del quarto trimestre e dell'intero anno 2024 per il 3 marzo 2025, dopo la chiusura del mercato. L'azienda ospiterà una conferenza telefonica e un webcast alle 16:30, ora orientale, per discutere i risultati e fornire un aggiornamento aziendale. Il management condurrà una sessione di domande e risposte per gli analisti, e una registrazione sarà disponibile sul sito web per gli investitori dell'azienda circa due ore dopo la conclusione della chiamata. Si consiglia ai partecipanti di unirsi 15 minuti prima dell'orario di inizio.
Biodesix (NASDAQ: BDSX) ha programado el anuncio de sus resultados financieros del cuarto trimestre y del año completo 2024 para el 3 de marzo de 2025, después del cierre del mercado. La compañía llevará a cabo una llamada de conferencia y un webcast a las 4:30 p.m., hora del Este, para discutir los resultados y proporcionar una actualización empresarial. La dirección realizará una sesión de preguntas y respuestas para analistas, y una grabación estará disponible en el sitio web de inversores de la empresa aproximadamente dos horas después de que termine la llamada. Se recomienda a los participantes unirse 15 minutos antes de la hora de inicio.
Biodesix (NASDAQ: BDSX)는 2025년 3월 3일 시장 종료 후 2024년 4분기 및 연간 재무 결과 발표를 예정하고 있습니다. 회사는 동부 표준시 기준 오후 4시 30분에 결과를 논의하고 비즈니스 업데이트를 제공하기 위해 컨퍼런스 콜과 웹캐스트를 개최할 것입니다. 경영진은 분석가를 위한 질문 및 답변 세션을 진행하며, 통화 종료 약 2시간 후에 회사의 투자자 웹사이트에서 재생이 가능합니다. 참가자는 시작 시간 15분 전에 참여하는 것이 권장됩니다.
Biodesix (NASDAQ: BDSX) a programmé l'annonce de ses résultats financiers du quatrième trimestre et de l'année entière 2024 pour le 3 mars 2025, après la clôture du marché. L'entreprise organisera une conférence téléphonique et un webcast à 16h30, heure de l'Est, pour discuter des résultats et fournir une mise à jour sur les activités. La direction animera une session de questions-réponses pour les analystes, et un enregistrement sera disponible sur le site web des investisseurs de l'entreprise environ deux heures après la fin de l'appel. Les participants sont invités à se connecter 15 minutes avant l'heure de début.
Biodesix (NASDAQ: BDSX) hat die Bekanntgabe seiner finanziellen Ergebnisse für das vierte Quartal und das Gesamtjahr 2024 auf den 3. März 2025, nach Marktschluss, terminiert. Das Unternehmen wird um 16:30 Uhr Eastern Time eine Telefonkonferenz und einen Webcast abhalten, um die Ergebnisse zu besprechen und ein Update zum Geschäft zu geben. Das Management wird eine Frage-und-Antwort-Runde für Analysten durchführen, und eine Aufzeichnung wird etwa zwei Stunden nach Abschluss des Anrufs auf der Investoren-Website des Unternehmens verfügbar sein. Teilnehmer werden empfohlen, 15 Minuten vor Beginn der Veranstaltung beizutreten.
- None.
- None.
BOULDER, Colo., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the fourth quarter and year ended December 31, 2024 after the close of trading on Monday, March 3. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.
Listeners can register for the webcast via this link. Analysts who wish to participate in the question and answer session should use this link. A replay of the webcast will be available via the company’s investor website approximately two hours after the call’s conclusion. Participants are advised to join 15 minutes prior to the start time.
About Biodesix
Biodesix is a leading diagnostic solutions company with five Medicare-covered tests available for pulmonology patients. The Nodify Lung® Nodule Risk Assessment evaluates the risk of malignancy in pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. The IQLung™ test portfolio for lung cancer patients supports treatment decisions across all stages of lung cancer and expedites personalized treatment. In addition, Biodesix collaborates with the world’s leading biopharmaceutical companies to provide biomarker discovery, diagnostic test development, and clinical trial support services. For more information, visit biodesix.com.
Trademarks: Biodesix, Biodesix Logo, Nodify Lung, and IQLung are trademarks or registered trademarks of Biodesix, Inc.
Note Regarding Forward-Looking Statements
This press release may contain forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical fact, are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “plan,” “expect,” “predict,” “potential,” “opportunity,” “goals,” or “should,” and similar expressions are intended to identify forward-looking statements. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors. Biodesix has based these forward-looking statements largely on its current expectations and projections about future events and trends. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions. Forward-looking statements may include information concerning the impact of backlog and the timing and assumptions regarding collection of revenues on projections, availability of funds and future capital including under the term loan facility, the anticipated impact and benefits of new clinical data, reimbursement coverage and research partnerships, and the impact of a pandemic, epidemic, or outbreak, including the COVID-19 pandemic, on Biodesix and its operations and financial performance. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. The Company's ability to continue as a going concern could cause actual results to differ materially from those contemplated in this press release and additionally, other factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Risk Factors section of Biodesix most recent annual report on Form 10-K, filed March 1, 2024 or subsequent quarterly reports on Form 10-Q during 2024, if applicable. Biodesix undertakes no obligation to revise or publicly release the results of any revision to such forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement.
Media:
Natalie St. Denis
Natalie.StDenis@biodesix.com
(720) 925-9285
Investors:
Chris Brinzey
chris.brinzey@icrhealthcare.com
(339) 970-2843
FAQ
When will Biodesix (BDSX) release its Q4 2024 earnings?
What time is Biodesix's (BDSX) Q4 2024 earnings call?
How can investors access Biodesix's (BDSX) Q4 2024 earnings call?
When will the replay of Biodesix's (BDSX) Q4 2024 earnings call be available?
